News Releases

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
10/15/2018
12:00 PM ET
Press Release

Diffusion Pharmaceuticals Chief Financial Officer William “Bill” Hornung to Present at 2018 BIO Investor Forum

10/15/2018

Over 1,000 Attendees Expected; Opportunity to Learn About Company’s FDA Approval for Phase 2 On-Ambulance Stroke Trial and Phase 3 GMB Brain Cancer Trial Enrollment

CHARLOTTESVILLE, Va., Oc...

 Continue Reading
9/25/2018
9:00 AM ET
Press Release

Diffusion Names William (“Bill”) Hornung Chief Financial Officer

9/25/2018

CHARLOTTESVILLE, Va., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical co...

 Continue Reading
9/12/2018
9:00 AM ET
Press Release

FDA Approves Start of Innovative On-Ambulance Phase 2 Clinical Trial for Treatment of Acute Stroke by Diffusion Pharmaceuticals

9/12/2018

CHARLOTTESVILLE, Va., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical co...

 Continue Reading
8/29/2018
8:00 AM ET
Press Release

Diffusion Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

8/29/2018

CHARLOTTESVILLE, Va., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on improving pati...

 Continue Reading
8/13/2018
8:30 AM ET
Press Release

Diffusion Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

8/13/2018

Enrollment continues in Phase 3 GBM brain cancer trialKey European patent validated covering oral formulation of TSCPreparing for Phase 2 stroke trial with in-ambulance administration of TSCCHARLOTTES...

 Continue Reading
6/12/2018
8:30 AM ET
Press Release

Diffusion Pharmaceuticals Announces Validation of European Patent for Oral Formulations of TSC

6/12/2018

CHARLOTTESVILLE, Va., June 12, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc.(NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the li...

 Continue Reading
5/29/2018
1:04 PM ET
Earnings Release

CORRECTION: Diffusion Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

5/29/2018

In the release issued under the same headline on May 10, 2018 by Diffusion Pharmaceuticals Inc. (Nasdaq:DFFN), please note that in the Consolidated Balance Sheets table, Cash and cash equivalents row,...

 Continue Reading
Displaying 1 to 7 (of 102 releases)